✦ LIBER ✦

Toward RNA interference-based therapy for filovirus infections

✍ Scribed by Kevin B. Spurgers; Lynn S. Silvestri; Kelly L. Warfield; Sina Bavari

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 142 KB
Volume: 70
Category: Article
ISSN: 0272-4391
DOI: 10.1002/ddr.20302

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

RNA interference for antiviral therapy

✍ Mali Ketzinel-Gilad; Yosef Shaul; Eithan Galun 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 335 KB 👁 1 views

## Abstract Silencing gene expression through a process known as RNA interference (RNAi) has been known in the plant world for many years. In recent years, knowledge of the prevalence of RNAi and the mechanism of gene silencing through RNAi has started to unfold. It is now believed that RNAi serves

Genetic Variability: The Key Problem in

Genetic Variability: The Key Problem in the Prevention and Therapy of RNA-Based Virus Infections.

✍ Magdalena Figlerowicz; Magdalena Alejska; Anna Kurzynska-Kokorniak; Marek Figler 📂 Article 📅 2003 🏛 John Wiley and Sons ⚖ 54 KB 👁 1 views

Modeling of congenital erythropoietic po

Modeling of congenital erythropoietic porphyria by RNA interference: a new tool for preclinical gene therapy evaluation

✍ Elodie Robert-Richard; Magalie Lalanne; Isabelle Lamrissi-Garcia; Véronique Guyo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB

## Abstract ## Background Congenital erythropoietic porphyria (CEP) is a severe autosomal recessive disorder characterized by a deficiency in uroporphyrinogen III synthase (UROS), the fourth enzyme of the heme biosynthetic pathway. We recently demonstrated the definitive cure of a murine model of

A One-Step Lysis Procedure for 18S Ribos

A One-Step Lysis Procedure for 18S Ribosomal RNA-Based Diagnosis of Infection byPlasmodiumSpecies

✍ Ashis Das; Altaf A. Lal; Gursaran P. Talwar; Seyed E. Hasnain; Subrata Sinha 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Depression and antiviral response to int

Depression and antiviral response to interferon-based therapy for hepatitis C virus infection

✍ Jennifer M. Loftis; Benjamin J. Morasco; Peter Hauser 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 378 KB 👁 1 views

We read with great interest the article by Stepanova et al. 1 In this report from the United States with 10,582 eligible individuals (1.52% of whom were positive for hepatitis C virus [HCV] antibody [anti-HCV]), the rate of insurance coverage was significantly lower in patients with HCV infection (6

Second-phase hepatitis C virus RNA decli

Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration

✍ Jeremie Guedj; Alan S. Perelson 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 442 KB 👁 1 views

Hepatitis C virus (HCV) RNA decay during antiviral therapy is characterized by a rapid first phase, followed by a slower second phase. The current understanding of viral kinetics attributes the magnitude of the first phase of decay to treatment effectiveness, whereas the second phase of decay is att